Page 71 - Read Online

Raczka et al. Cancer Drug Resist 2019;2:356-64 I http://dx.doi.org/10.20517/cdr.2018.004 Page 363

12. Zarrabi K, Fang C, Wu S. New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. J Hematol
Oncol 2017;10:38.
13. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind,
randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
14. Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-52.
15. Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2015;7:365-77.
16. Frei E, Karon M, Levin RH, Freireich EJ, Taylor RJ, et al. The effectiveness of combinations of antileukemic agents in inducing and
maintaining remission in children with acute leukemia. Blood 1965;26:642-56.
17. Komarova EA, Gudkov AV. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors.
Biochem Pharmacol 2001;62:657-67.
18. Chong CR, Sullivan Jr DJ. New uses for old drugs. Nature 2007;448:645-6.
19. Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, et al. Lenvatinib, everolimus, and the combination in patients with
metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 2015;16:1473-82.
20. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic
renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
21. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with
metastatic renal cell carcinoma (AVOREN): Final Analysis of Overall Survival. J Clin Oncol 2010;28:2144-50.
22. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, et al. Nivolumab plus Ipilimumab versus sunitinib in advanced
renal-cell carcinoma. N Engl J Med 2018;378:1277-90.
23. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. Available from:
https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm604685.htm. [Last accessed on 24 Apr 2019].
24. Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, et al. IMmotion151: a randomized phase iii study of atezolizumab plus
bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC). J Clin Oncol 2018;36:578.
25. Lee CH, Makker V, Rasco D, Taylor M, Stepan D, et al. Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated
results. J Clin Oncol 2018;36:4560
26. Apolo A, Mortazavi A, Stein M, Davarpanah N, Nadal R, et al. A phase I study of cabozantinib plus nivolumab (CaboNivo) and
cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic (m) urothelial carcinoma (UC) and other
genitourinary (GU) tumors. J Clin Oncol 2017;35:4562.
27. Nadal R, Mortazavi A, Stein M, Pal S, Davarpanah N, et al. Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus
nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other
genitourinary (GU) malignancies. J Clin Oncol 2018;36:515.
28. Escudier B, Barthelemy P, Ravaud A, Negrier S, Needle M, et al. Tivozanib combined with nivolumab: Phase Ib/II study in metastatic
renal cell carcinoma (mRCC). J Clin Oncol 2018;36:618.
29. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell 2011;144:646-74.
30. Vander Heiden M, Cantley L, Thompson C. Understanding the warburg effect: the metabolic requirements of cell proliferation. Science
2009;324:1029-33.
31. Carr E, Kelman A, Wu G, Gopaul R, Senkevitch E, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK
during T lymphocyte activation. J Immunol 2010;185:1037-44.
32. Lukey MJ, Wilson KF, Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem
2013;5:1685-700.
33. Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther
1990;46:243-71.
34. Ovejera A, Houchens D, Catane R, Sheridan M, Muggia F. Efficacy of 6-Diazo-5-oxo-l-norleucine and N-[N-γ-Glutamyl-6-diazo-5-
oxo-norleucinyl]-6-diazo-5-oxo-norleucine against experimental tumors in conventional and nude mice. Cancer Res 1979;39:3220-4.
35. Mueller C, Al-Batran S, Jaeger E, Schmidt B, Bausch M, et al. A phase IIa study of PEGylated glutaminase (PEG-PGA) plus 6-diazo-5-
oxo-L-norleucine (DON) in patients with advanced refractory solid tumors. J Clin Oncol 2008;26:2533.
36. DeLaBarre B, Gross S, Fang C, Gao Y, Jha A, et al. Full-length human glutaminase in complex with an allosteric inhibitor. Biochemistry
2011;50:10764-70.
37. Robinson M, McBryant S, Tsukamoto T, Rojas C, Ferraris D, et al. Novel mechanism of inhibition of rat kidney-type glutaminase by
bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007;406:407-14.
38. Le A, Lane A, Hamaker M, Bose S, Gouw A, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and
survival in B cells. Cell metabolism 2012;15:110-21.
39. Shukla K, Ferraris DV, Thomas AG, Stathis M, Duvall B, et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-
phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 2012;55:10551-63.
40. Matre P, Velez J, Jacamo R, Qi Y, Su X, et al. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML
subtypes. Oncotarget 2016;7:79722-35.
41. Parlati F, Gross M, Janes J, Lewis E, MacKinnon A, Rodriguez M, et al. Glutaminase Inhibitor CB-839 Synergizes with Pomalidomide
in Preclinical Multiple Myeloma Models. Blood. 2014;124:4720.
42. Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-
negative breast cancer. Mol Cancer Ther 2014;13:890-901.
43. Lampa M, Arlt H, He T, Ospina B, Reeves J, et al. Glutaminase is essential for the growth of triple-negative breast cancer cells with a